At 11.4% CAGR, the North America Intradermal Injection Market is projected to be worth US$ 2,859.32 million by 2028, says Business Market Insights         

According to the Insight Partners’ research, the North America intradermal injection market was valued at US$ 1,342.54 million in 2021 and is expected to reach US$ 2,859.32 million by 2028, registering an annual growth rate of 11.4% from 2021 to 2028.Rising acceptance of aesthetic procedures and strategic developments by manufacturers are the critical factors attributed to the market expansion.                

Aesthetic procedures are defined as methods used for altering the physical appearance and they are considered under the category of cosmetic surgeries. Recently, rapid increase in the aesthetic procedures is observed at global level and many of the leading aesthetic procedures involve the use of intradermal injections. As per the data of the Aesthetic Plastic Surgery National Databank, more than 7 million aesthetic procedures were performed in US during 2020 among which the leading segment was toxins and fillers with about 3.9 million procedures. Neurotoxins related aesthetic procedures are the leading one and intradermal injections are mainly used for delivering various neurotoxins and ultimately increasing the demand of intradermal injections. Further, the other developing countries including Canada, are also adapting the cosmetic surgeries and hence it will act as major driver for the growth of this segment.  

On the contrary, risks, complications, and dosing limitations associated with intradermal injections hurdles the growth of North America intradermal injection market. 

• Based on method, the North America intradermal injection market is segmented into normal sized needles, short needle, and without needle. The normal sized needles segment held 38.0% market share in 2021, amassing US$ 510.60 million. It is projected to garner US$ 1,047.79 million by 2028 to expand at 10.8% CAGR during 2021–2028. The normal sized needles segment is further subsegmented into intradermal microinjection, microneedle arrays, and tattoo devices. The short needle segment is further subsegmented intradermal liquid jet injectors and ballistic intradermal injectors.
• Based on application, the North America intradermal injection market is segmented into tuberculin skin test, allergy test, local aesthetics, and others. The tuberculin skin test segment held 29.0% market share in 2021, amassing US$ 389.26 million. It is projected to garner US$ 815.69 million by 2028 to expand at 11.1% CAGR during 2021–2028.
• Based on end user, the North America intradermal injection market is segmented into hospitals, diagnostic laboratories, academics and research institutes, and others. The hospitals segment held 39.8% market share in 2021, amassing US$ 534.76 million. It is projected to garner US$ 1,149.05 million by 2028 to expand at 11.5% CAGR during 2021–2028.
• Based on country, the North America intradermal injection market has been categorized into US, Canada, and Mexico.  Our regional analysis states that US captured 81.5% market share in 2021. It was assessed at US$ 1,093.91 million in 2021 and is likely to hit US$ 2,358.05 million by 2028, exhibiting a CAGR of 11.6% during the forecast period.  

Key players profiles in the North America intradermal injection market report are BD; West Pharmaceutical Services, Inc; Terumo Corporation; Nanopass; PharmaJet; Idevax; Eunsung Global; Crossject; Cardinal Health Inc; and Hindustan Syringes and Medical Devices Ltd among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com